MedPath

igella Sativa oil for treatment of Behcet's disease

Phase 1
Conditions
Behcet’s Disease.
Behcet’s Disease, unspecified
Registration Number
IRCT201511086975N5
Lead Sponsor
Vice chancellor for research, Tabriz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
88
Inclusion Criteria

Age older than 16; Having active Behcet’s disease: Iranian's Behcet's Disease Dynamic Activity Measure (IBDDAM) more than 2.5
Exclusion criteria: Consumption of Nigella Sativa oil supplements in the past 8 weeks; Pregnancy and lactation; Liver disease; Renal insufficiency

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Behcet's disease activity. Timepoint: Before, 2, 4, and 6 months after intervention. Method of measurement: Iranian's Behcet's disease activity measure.;Plasma levels of TNF-a, IL-10, oxidant and antioxidant systems (total antioxidant, malondialdehyde). Timepoint: Before and 2 months after intervention. Method of measurement: Enzyme-Linked Immunosorbent Assay.
Secondary Outcome Measures
NameTimeMethod
igella Sativa oil side effects. Timepoint: 2, 4, and 6 months after intervention. Method of measurement: Questionnaire.
© Copyright 2025. All Rights Reserved by MedPath